Oxford Immunotec Global (OXFD) Downgraded by BidaskClub

BidaskClub downgraded shares of Oxford Immunotec Global (NASDAQ:OXFD) from a hold rating to a sell rating in a research report report published on Saturday morning.

OXFD has been the topic of several other research reports. Zacks Investment Research cut shares of Oxford Immunotec Global from a hold rating to a sell rating in a report on Wednesday, August 30th. Cowen reaffirmed a buy rating and issued a $19.00 price target on shares of Oxford Immunotec Global in a research note on Thursday, September 28th. BTIG Research set a $21.00 price target on Oxford Immunotec Global and gave the stock a buy rating in a research note on Tuesday, October 31st. Robert W. Baird reaffirmed a buy rating and issued a $20.00 price target on shares of Oxford Immunotec Global in a research note on Wednesday, November 1st. Finally, ValuEngine lowered Oxford Immunotec Global from a hold rating to a sell rating in a research note on Tuesday, October 31st. Three analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Oxford Immunotec Global has an average rating of Hold and an average target price of $19.75.

Oxford Immunotec Global (NASDAQ:OXFD) opened at $13.04 on Friday. The company has a current ratio of 4.72, a quick ratio of 4.30 and a debt-to-equity ratio of 0.38. Oxford Immunotec Global has a fifty-two week low of $12.19 and a fifty-two week high of $19.51.

In other Oxford Immunotec Global news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $13.35, for a total transaction of $40,050.00. Following the completion of the transaction, the director now owns 17,778 shares of the company’s stock, valued at $237,336.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. Company insiders own 8.11% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Cortina Asset Management LLC lifted its position in Oxford Immunotec Global by 12.8% during the third quarter. Cortina Asset Management LLC now owns 563,290 shares of the company’s stock valued at $9,463,000 after buying an additional 63,765 shares during the period. Wasatch Advisors Inc. lifted its position in Oxford Immunotec Global by 35.5% during the third quarter. Wasatch Advisors Inc. now owns 574,174 shares of the company’s stock valued at $9,646,000 after buying an additional 150,343 shares during the period. Teachers Advisors LLC lifted its position in Oxford Immunotec Global by 20.5% during the second quarter. Teachers Advisors LLC now owns 55,674 shares of the company’s stock valued at $936,000 after buying an additional 9,474 shares during the period. Bank of New York Mellon Corp lifted its position in Oxford Immunotec Global by 13.5% during the second quarter. Bank of New York Mellon Corp now owns 62,566 shares of the company’s stock valued at $1,052,000 after buying an additional 7,435 shares during the period. Finally, Northern Trust Corp lifted its position in Oxford Immunotec Global by 20.0% during the second quarter. Northern Trust Corp now owns 243,961 shares of the company’s stock valued at $4,104,000 after buying an additional 40,637 shares during the period. 89.35% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: This story was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this story on another publication, it was illegally stolen and republished in violation of U.S. & international trademark & copyright law. The correct version of this story can be viewed at https://www.truebluetribune.com/2017/12/12/oxford-immunotec-global-oxfd-downgraded-by-bidaskclub.html.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply